<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta http-equiv="Cache-Control" content="no-cache, no-store, must-revalidate">
    <meta http-equiv="Pragma" content="no-cache">
    <meta http-equiv="Expires" content="0">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Selection Criteria - CRLM LT Clinical Resource</title>
    <link rel="stylesheet" href="../css/style.css?v=1765110448">
</head>
<body>
    <!-- Navigation -->
    <nav class="navbar">
        <div class="container">
            <div class="logo">CRLM LT Resource</div>
            <button class="hamburger" id="hamburger" aria-label="Toggle menu">
                <span></span>
                <span></span>
                <span></span>
            </button>
            <ul class="nav-menu" id="navMenu">
                <li><a href="../index.html">Home</a></li>
                <li><a href="overview.html">Overview</a></li>
                <li><a href="selection-criteria.html" class="active">Selection Criteria</a></li>
                <li><a href="outcomes.html">Clinical Outcomes</a></li>
                <li><a href="lt-vs-resection.html">LT vs Resection</a></li>
                <li><a href="survival-curves.html">Survival Curves</a></li>
                <li><a href="pdf-resources.html">PDF Resources</a></li>
                <li><a href="patient-flowchart.html">Patient Flowchart</a></li>
                <li><a href="resources.html">Resources</a></li>
                <li><a href="about-research-group.html">About Research Group</a></li>
            </ul>
        </div>
    </nav>

    <!-- Main Content -->
    <main class="content">
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">Home</a> / Selection Criteria
            </div>

            <h1>Patient Selection Criteria for LT in CRLM</h1>

            <section class="section">
                <h2>Overview</h2>
                <p>The success of LT for CRLM depends critically on rigorous patient selection. Multiple scoring systems and prognostic factors have been developed to identify patients with favorable tumor biology who will benefit most from transplantation.</p>
            </section>

            <section class="section">
                <h2>The Oslo Score</h2>
                <p>The Oslo Score was developed from the SECA-I trial and is one of the most widely used tools for predicting post-LT survival in CRLM patients.</p>

                <div class="scoring-system">
                    <h3>Oslo Score Components (1 point each)</h3>
                    <div class="score-item">
                        <div class="score-criterion">
                            <strong>1. Largest Tumor Size ≥ 5.5 cm</strong>
                            <p>Larger tumors indicate greater disease burden and are associated with worse outcomes.</p>
                        </div>
                    </div>
                    <div class="score-item">
                        <div class="score-criterion">
                            <strong>2. Progressive Disease on Chemotherapy</strong>
                            <p>Disease progression despite systemic therapy indicates aggressive biology.</p>
                        </div>
                    </div>
                    <div class="score-item">
                        <div class="score-criterion">
                            <strong>3. Plasma CEA Level > 80 µg/L</strong>
                            <p>Elevated CEA suggests higher tumor burden and poorer prognosis.</p>
                        </div>
                    </div>
                    <div class="score-item">
                        <div class="score-criterion">
                            <strong>4. Time from Primary Tumor Resection to LT < 2 Years</strong>
                            <p>Short interval suggests rapid metastatic progression.</p>
                        </div>
                    </div>
                </div>

                <h3>Oslo Score Interpretation</h3>
                <table class="data-table">
                    <tr>
                        <th>Oslo Score</th>
                        <th>5-Year OS</th>
                        <th>10-Year OS</th>
                        <th>Risk Category</th>
                    </tr>
                    <tr class="favorable">
                        <td><strong>0-1</strong></td>
                        <td>63.4% - 92.0%</td>
                        <td>45.7% - 88.9%</td>
                        <td>Favorable</td>
                    </tr>
                    <tr class="intermediate">
                        <td><strong>2</strong></td>
                        <td>~60%</td>
                        <td>~45%</td>
                        <td>Intermediate</td>
                    </tr>
                    <tr class="unfavorable">
                        <td><strong>3-4</strong></td>
                        <td>8.3%</td>
                        <td>0%</td>
                        <td>Unfavorable</td>
                    </tr>
                </table>

                <div class="clinical-note">
                    <strong>Clinical Note:</strong> An Oslo Score of 0-2 is generally considered acceptable for LT consideration, while scores of 3-4 are associated with poor outcomes and should generally be excluded.
                </div>
            </section>

            <section class="section">
                <h2>Fong Clinical Risk Score (FCRS)</h2>
                <p>The FCRS was originally developed for liver resection but has been validated for LT in CRLM patients.</p>

                <div class="scoring-system">
                    <h3>FCRS Components (1 point each)</h3>
                    <div class="score-item">
                        <div class="score-criterion">
                            <strong>1. Node-Positive Primary Tumor</strong>
                        </div>
                    </div>
                    <div class="score-item">
                        <div class="score-criterion">
                            <strong>2. Disease-Free Interval < 12 Months</strong>
                        </div>
                    </div>
                    <div class="score-item">
                        <div class="score-criterion">
                            <strong>3. More Than 1 Liver Tumor</strong>
                        </div>
                    </div>
                    <div class="score-item">
                        <div class="score-criterion">
                            <strong>4. Preoperative CEA > 200 ng/mL</strong>
                        </div>
                    </div>
                    <div class="score-item">
                        <div class="score-criterion">
                            <strong>5. Size of Largest Tumor > 5 cm</strong>
                        </div>
                    </div>
                </div>

                <h3>FCRS Interpretation</h3>
                <table class="data-table">
                    <tr>
                        <th>FCRS</th>
                        <th>5-Year OS</th>
                        <th>Risk Category</th>
                    </tr>
                    <tr class="favorable">
                        <td><strong>0-2</strong></td>
                        <td>75% - 80%</td>
                        <td>Favorable</td>
                    </tr>
                    <tr class="unfavorable">
                        <td><strong>≥ 3</strong></td>
                        <td>40%</td>
                        <td>Unfavorable</td>
                    </tr>
                </table>
            </section>

            <section class="section">
                <h2>Metabolic Tumor Volume (PET-MTV)</h2>
                <p>18F-FDG PET/CT is essential for excluding extrahepatic disease and quantifying disease burden. The metabolic tumor volume (MTV) is a powerful prognostic factor.</p>

                <div class="highlight-box">
                    <h3>PET-MTV Prognostic Value</h3>
                    <table class="data-table">
                        <tr>
                            <th>PET-MTV</th>
                            <th>3-Year OS</th>
                            <th>5-Year OS</th>
                        </tr>
                        <tr class="favorable">
                            <td><strong>&lt; 70 cm³</strong></td>
                            <td>90.9%</td>
                            <td>63.6%</td>
                        </tr>
                        <tr class="unfavorable">
                            <td><strong>≥ 70 cm³</strong></td>
                            <td>50%</td>
                            <td>25%</td>
                        </tr>
                    </table>
                </div>

                <p><strong>Clinical Application:</strong> PET-MTV &lt; 70 cm³ is associated with significantly improved outcomes and should be used as a selection criterion.</p>
            </section>

            <section class="section">
                <h2>Molecular Prognostic Factors</h2>
                <p>Recent advances in molecular profiling have identified specific genetic alterations that predict response to LT and post-transplant survival.</p>

                <h3>RAS/TP53 Co-mutations</h3>
                <div class="warning-box">
                    <p><strong>Negative Prognostic Impact:</strong> Co-mutations of RAS and TP53 are associated with significantly worse outcomes:</p>
                    <ul>
                        <li><strong>Median OS with RAS/TP53 co-mutations:</strong> 21 months</li>
                        <li><strong>Median OS without co-mutations:</strong> 60 months</li>
                        <li><strong>Hazard Ratio:</strong> 4.0 (95% CI 1.7-9.3)</li>
                    </ul>
                    <p><strong>Recommendation:</strong> Patients with RAS/TP53 co-mutations should be carefully counseled and may be better served by alternative treatment strategies.</p>
                </div>

                <h3>BRAF V600E Mutation</h3>
                <div class="warning-box">
                    <p><strong>Exclusion Criterion:</strong> BRAF V600E mutations are associated with poor prognosis and aggressive disease. Patients with this mutation should be excluded from LT consideration per IHPBA consensus guidelines.</p>
                </div>

                <h3>Microsatellite Instability and Mismatch Repair Status</h3>
                <p>IHPBA guidelines recommend that patients must have microsatellite stability and be mismatch repair proficient to be considered for LT.</p>
            </section>

            <section class="section">
                <h2>IHPBA Consensus Exclusion Criteria</h2>
                <p>The International Hepato-Pancreato-Biliary Association has established clear exclusion criteria for LT in CRLM:</p>

                <div class="exclusion-criteria">
                    <h3>Pathological Exclusions</h3>
                    <ul>
                        <li>Undifferentiated adenocarcinoma histology</li>
                        <li>Signet ring cell carcinoma</li>
                        <li>Extensive nodal disease (N2 or greater)</li>
                        <li>BRAF V600E mutation</li>
                        <li>Microsatellite instability or mismatch repair deficiency</li>
                    </ul>

                    <h3>Radiological/Clinical Exclusions</h3>
                    <ul>
                        <li>Extrahepatic metastases (except prior resected pulmonary metastases)</li>
                        <li>Local recurrence of primary tumor</li>
                        <li>Inadequate response to bridging chemotherapy</li>
                    </ul>

                    <h3>General Transplant Exclusions</h3>
                    <ul>
                        <li>Active infection or uncontrolled sepsis</li>
                        <li>Significant comorbidities precluding surgery</li>
                        <li>Poor performance status (ECOG &gt; 1)</li>
                        <li>Active substance abuse</li>
                    </ul>
                </div>
            </section>

            <section class="section">
                <h2>Recommended Evaluation Protocol</h2>
                <div class="protocol-box">
                    <h3>Pre-Transplant Workup</h3>
                    <ol>
                        <li><strong>Imaging:</strong> Contrast-enhanced CT or MRI of liver + 18F-FDG PET/CT</li>
                        <li><strong>Tumor Markers:</strong> CEA level</li>
                        <li><strong>Molecular Testing:</strong> KRAS, NRAS, BRAF, TP53 mutations; microsatellite instability status</li>
                        <li><strong>Chemotherapy Response:</strong> Assess response to ≥3 months of systemic therapy</li>
                        <li><strong>Scoring:</strong> Calculate Oslo Score, FCRS, and PET-MTV</li>
                        <li><strong>Multidisciplinary Review:</strong> Oncology, surgery, transplant, and radiology consensus</li>
                    </ol>
                </div>
            </section>

            <section class="section call-to-action">
                <h2>Next Steps</h2>
                <p>Once you've assessed patient selection criteria, review the <a href="outcomes.html">Clinical Outcomes</a> page to understand expected survival and recurrence patterns.</p>
            </section>
        </div>
    </main>

    <!-- Footer -->
    <footer class="footer">
        <div class="container">
            <p>&copy; 2025 CRLM LT Clinical Resource. Evidence-based information for transplant teams.</p>
            <p class="author"><strong>Created by:</strong> Tor Magnus Smedman, MD PhD | Transplant Oncology Research Group, Oslo University Hospital</p>
            <p class="disclaimer">This resource is for educational purposes. Clinical decisions should be made in consultation with a multidisciplinary team.</p>
        </div>
    </footer>

    <script src="../js/main.js?v=1765110448"></script>
    <script>
        // Hamburger menu toggle
        const hamburger = document.getElementById("hamburger");
        const navMenu = document.getElementById("navMenu");
        
        if (hamburger && navMenu) {
            hamburger.addEventListener("click", function() {
                navMenu.classList.toggle("active");
                hamburger.classList.toggle("active");
            });
            
            // Close menu when a link is clicked
            const navLinks = navMenu.querySelectorAll("a");
            navLinks.forEach(link => {
                link.addEventListener("click", function() {
                    navMenu.classList.remove("active");
                    hamburger.classList.remove("active");
                });
            });
        }
    </script>
</body>
</html>
